StockNews.com Initiates Coverage on Eagle Pharmaceuticals (NASDAQ:EGRX)

StockNews.com assumed coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a report issued on Saturday morning. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Trading Down 11.1 %

EGRX stock opened at $0.80 on Friday. Eagle Pharmaceuticals has a fifty-two week low of $0.00 and a fifty-two week high of $6.81. The business’s fifty day moving average price is $0.68 and its two-hundred day moving average price is $2.17.

Institutional Trading of Eagle Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Creative Planning bought a new position in shares of Eagle Pharmaceuticals during the 3rd quarter worth approximately $59,000. Mackenzie Financial Corp bought a new position in shares of Eagle Pharmaceuticals in the second quarter worth approximately $60,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Eagle Pharmaceuticals in the second quarter worth approximately $65,000. Jane Street Group LLC purchased a new position in shares of Eagle Pharmaceuticals in the third quarter worth $96,000. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of Eagle Pharmaceuticals during the second quarter valued at about $145,000. 85.36% of the stock is owned by institutional investors.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.